European Journal of Cardiovascular Medicine

Background and objectives: In situ hybridization (IHC) markers p63, SMA, and ki67 in the spectrum of ductal proliferative breast lesions: a study employing excision biopsy and mastectomy patients. The goal of this study is to evaluate myoepithelial markers for their potential in spotting breast cancer in its earliest stages. Methods: The research used representative paraffin sections from 30 breast mass tissue samples submitted to the Department of Pathology, Osmania Medical College, Hyderabad, Telangana, India, between April 2018 to March 2019. P63, SMA, and Ki 67 antibodies were used to immunostain 40 breast masses categorised as ductal proliferative lesions, ductal carcinoma in situ, or invasive ductal carcinoma by the Department of Pathology. Results: p63 non myoepithelial had 22 in negative frequency and 8 in positive frequency. While for SMA nonmyoepithelial negative frequency was 4 and positive frequency was 16. Over and over, it was shown that stromal cells, and myofibroblasts in particular, did not react to the stimuli. There was a ring of p63-immunoreactive cells encircling lobular and ductal cancer in situ, however it was disjointed compared to the normal structures. Conclusion: Ki67, myoepithelial P63, and stromal myoepithelial antigen (SMA) were shown to be reliable markers for discriminating normal epithelium from hyperplasia, MIN, and invasive carcinoma in this study.